

Time to Surgery Does Not Influence Survival Outcome in Patients With Upfront Resected Pancreatic Adenocarcinoma

Mathias Brugel (✉ mbrugel@chu-reims.fr)

Centre Hospitalier Universitaire de Reims

Olivier Bouché

Centre Hospitalier Universitaire de Reims

Reza Kianmanesh

Centre Hospitalier Universitaire de Reims

Lugdivine Teuma

Centre Hospitalier Universitaire de Reims

Ahmad Tashkandi

Centre Hospitalier Universitaire de Reims

Jean Marc Regimbeau

CHU Amiens Picardie

Patrick Pessaux

Nouvel Hôpital Civil

Benoit Royer

Clinique de Courlancy

Rami Rhaïem

Centre Hospitalier Universitaire de Reims

Cyril Perrenot

Centre Hospitalier Universitaire de Reims

Cindy Neuzillet

Institut Curie, Versailles Saint-Quentin University, Paris Saclay University

Tullio Piardi

Centre Hospitalier Universitaire de Reims

Sophie Deguelte

Centre Hospitalier Universitaire de Reims

Research Article

Keywords: pancreatic adenocarcinoma, resectable, delay, time to surgery

Posted Date: August 24th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-677403/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background

This study evaluated the impact of time to surgery (TTS) on overall survival (OS), disease free survival (DFS) and postoperative complication rate in patients with upfront resected pancreatic adenocarcinoma (PA).

Methods

We retrospectively included patients who underwent upfront surgery for PA between January 1, 2004 and December 31, 2014 from four French centers. TTS was defined as the number of days between the date of the first consultation in specialist care and the date of surgery. DFS for a 14-day TTS was the primary endpoint. We also analyzed survival depending on different delay cut-offs (7, 14, 28, 60 and 75 days).

Results

A total of 168 patients were included. 59 patients (35%) underwent an upfront surgery within 14 days. Patients in the higher delay group had significantly more vein resections and endoscopic biliary drainage. Adjusted OS ($p = 0.44$), DFS ($p = 0.99$), fistulas ($p = 0.41$), hemorrhage ($p = 0.59$) and severe post-operative complications ($p = 0.82$) were similar in both groups. Other delay cut-offs had no impact on OS or DFS.

Discussion

TTS seems to have no impact on OS, DFS and 90-day postoperative morbidity.

Introduction

Pancreatic adenocarcinoma (PA) is one of the most aggressive digestive cancers. Five-year overall survival (OS) rate is estimated below 8% (all stages combined)(1). This malignancy is expected to be the second leading cause of cancer-related death in Europe by 2030(2).

Actual standard of care for resectable PA is upfront carcinologic surgery followed by adjuvant chemotherapy(3). Unfortunately, prognosis remains poor despite improvements in surgical technique, perioperative care, diagnosis accuracy, patient selection and more active chemotherapy regimen(4). New perspectives are needed to increase both survival rates and quality of life for patients diagnosed with PA.

One of the objectives studied in other cancers has been to reduce time to treatment by improving the organization of the care pathway. Time to surgery (TTS) has turned out to be a major prognostic factor associated with survival in several malignancies(5–8). To date, the impact of TTS on OS and disease-free survival (DFS) in patients diagnosed with resectable PA remains unclear(9).

Moreover, pancreatic resection is one of the most challenging surgery, with significant postoperative morbidity and mortality(10). Improving preoperative status – by means of biliary drainage, hemostasis correction, prehabilitation with nutritional and adapted physical activity interventions(11) – is needed before surgery as complications are more frequent in unfit patients(12). Shorter TTS may not allow to optimize prehabilitation but could improve carcinologic prognosis.

This study evaluated the impact of TTS on OS, DFS and postoperative complication rate in patients who underwent upfront curative intent surgical resection of a PA.

Material And Methods

We retrospectively included patients with upfront resected PA between January 1, 2004 and December 31, 2014 in three tertiary French centers (Reims University Hospital, Amiens University Hospital, Strasbourg University Hospital) and in one private center

(Reims Courlancy Clinic). Patients were screened with administrative coding and multidisciplinary tumor board meetings data (MTBM). All MTBM applied the consensus of the International Study Group of Pancreatic Surgery requiring the expertise of a senior radiologist and a pancreatic surgeon(13).

All patients who underwent upfront curative intent resection for a PA were included. Patients were excluded in case of neoadjuvant treatment or incomplete surgical resection (R2).

Basic baseline clinical, biological (i.e. ECOG performance status (PS), initial symptoms, tumor location, preoperative biliary drainage, bilirubin levels and neutrophil-lymphocyte ratio), pathological and surgical data (i.e. TNM staging, lymph node ratio [number of invaded lymph nodes/total number of resected lymph nodes], resection margins [R0 or R1], venous and adjacent organ involvement [gastric, colon or left adrenal resection]), were collected using medical records. Follow up characteristics such as postoperative complications, adjuvant treatment regimen and evolution of the disease (tumor recurrence, site of recurrence and death) were also collected.

Time to decision (TTD) was defined as the delay in days between first specialized medical interview (gastroenterologist, pancreatic surgeon, or medical oncologist) and MTBM decision. Time to surgery (TTS) was defined as the delay between the first specialized medical interview (gastroenterologist, pancreatic surgeon, medical oncologist) and surgery. The 90-day postoperative complications were assessed using Dindo-Clavien classification(14). Grade III or higher grade complications were considered as severe(14). Follow-up was standard and left to the physician's discretion according to guidelines prevailing at the time of the treatment(3). The primary objective was to determine the impact of a shorter (≤ 14 days) TTS in DFS improvement. This threshold was chosen in accordance with literature review and the investigators' experience(15–20). Secondary objectives were to evaluate OS and DFS according to other TTS and TTD thresholds (7-, 14-, 28-, 60- and 75-day delay). Ninety-day morbidity rate was compared using a 14-day delay. Endpoint date was set to provide at least a 12-month follow-up (December 31, 2015).

Statistical analysis

Continuous variables were described as median and interquartile ranges. Categorical variables were described as frequencies expressed with percentages. Groups with different management delays were compared using Mann-Whitney test (non-normal continuous variables) and Chi square test or Fisher test (categorical variables), depending on variable type and sample size. OS was calculated from date of surgery procedure to date of death or censoring at the date of last visit. DFS was calculated from the date of the surgical procedure to the date of progression, death or censoring at the date of last visit(9). Survival curves were established using the Kaplan-Meier method and compared using Cox proportional-hazards model for univariate and multivariate analyses. We pre-planned several survival analyses stratified on different delay cut-offs (7, 14, 28, 60 and 75 days).

Complication rates were analyzed according to a 14-day delay using Mann-Whitney test and logistic regression adjusted for factors with a $p < 0.2$ in stepwise regression. All data analyses were performed using R (R Development Core Team, 2005).

Statistical significance was defined as a p value < 0.05 for all tests.

Ethics

Patient's records were anonymized prior to analysis. Database was constituted in accordance with the reference methodology MR004 of the National Commission of Liberties and Informatics. (n°2206749, 13/09/2018). As per French regulations, no additional ethical review was required.

Results

Population characteristics at baseline

A total of 534 patients with a PA were screened. Among them, 201 patients underwent an upfront surgery procedure with curative intent; 33 were finally excluded due to unresectable tumor upon surgical reassessment (27) or insufficient data collection (6). The study flowchart is presented in Fig. 1 (Flowchart).

Patient characteristics are presented in Table 1. Most patients were men (57.7%), with a median age of 66 years (IQR :58–71). ECOG PS was available in 60.2% of the cases. Only four patients were ECOG PS > 1. Jaundice was the main symptom (69%) at first patient visit, and diagnosis was made during a hospital stay in 44.6% of the cases. Tumors were mainly located in the head of the pancreas (79.8%), warranting a biliary drainage in 64 patients (38.1%). Median total bilirubin prior to any biliary drainage was 197.5 μ mol/L (IQR :135.5–336.75).

Table 1
A. Baseline characteristics

Characteristics	n = 168
Inclusion center (%)	
Reims University Hospital	70 (41.7)
Reims Courlancy Clinic	12 (7.1)
Amiens University Hospital	60 (35.7)
Strasbourg University Hospital	26 (15.5)
Male (%)	71 (57.7)
Age, years (median [IQR])	66 [58.00, 71.00]
BMI, kg/m ² (median [IQR])	25.33 [22.49, 28.58]
Performance status (%)	
0	70 (41.7)
1	27 (16.1)
2	4 (2.4)
NA	67 (39.9)
Clinical symptoms at presentation (%)	
Jaundice	116 (69.0)
Abdominal pain	53 (31.5)
Weight loss	5 (3.0)
Incidentaloma	6 (3.6)
Other	26 (15.5)
NA	1 (0.6)
Diagnosed during hospital stay (%)	75 (44.6)
Imaging technique used for diagnosis (%)	
Computed tomography	85 (50.6)
Echography	18 (10.7)
Echoendoscopy	37 (22.0)
MRI	21 (12.5)
Other	5 (3.0)
NA	2 (1.2)
Tumor location (%)	
Head	134 (79.8)
Body	13 (7.7)
Tail	18 (10.7)
NA	3 (1.8)

Characteristics	n = 168
Lymphadenopathy at imaging (%)	27 (16.1)
Endoscopic biliary drainage (%)	58 (34.5)
Radiological biliary drainage (%)	6 (3.6)
Total bilirubin ($\mu\text{mol/L}$) (median [IQR])	54.00 [9.47, 185.25]
Conjugated bilirubin ($\mu\text{mol/L}$) (median [IQR])	46.00 [7.20, 148.50]
Neutrophils to lymphocytes ratio (median [IQR]) [†]	2.67 [2.00, 3.82]
Time to decision (days) (median [IQR])	9.50 [1.00, 30.50]
Time to surgery (days) (median [IQR])	19.00 [12.00, 36.00]

Table 1
B. Surgery procedure, histopathological, and follow up characteristics

Characteristics	n = 168
Type of resection (%)	
Pancreaticoduodenectomy	131 (78.0)
Splenopancreatectomy	28 (16.7)
Left pancreatectomy	4 (2.4)
Total pancreatectomy	5 (3.0)
Vein resection (%)	69 (41.1)
Organ resection (%) ^{*†}	10 (6.0)
T (%)	
1	3 (1.8)
2	25 (14.9)
3	128 (76.2)
4	9 (5.4)
x	1 (0.6)
NA	2 (1.2)
N (%) [†]	
0	37 (22.0)
1	129 (76.8)
x	1 (0.6)
NA	1 (0.6)
M (%) ^{*†}	
0	157 (93.5)
1	9 (5.4)
x	2 (1.2)
Number of lymphatic nodes sampled (median [IQR])	19.00 [12.00, 25.00]
Number of invaded lymph nodes (median [IQR]) [†]	2.00 [1.00, 4.00]
Invaded/sampled lymph nodes (median [IQR])	0.08 [0.00, 0.20]
Resection status (%) [†]	
0	105 (62.5)
1	62 (36.9)
NA	1 (0.6)

Footnotes : n :total population ; IQR :interquartile range ; kg/m² :kilograms per square meter ; BMI :body mass index ; NA :not available ; MRI :magnetic resonance imaging ; * variable associated with overall survival using univariate Cox proportional-hazards model ; † variable associated with disease free survival using univariate Cox proportional-hazards model

Characteristics	n = 168
Microscopic vascular invasion (%)	
Yes	103 (61.3)
No	25 (14.9)
NA	40 (23.8)
Perineural invasion (%)	
Yes	137 (81.5)
No	10 (6.0)
NA	21 (12.5)
Length of stay (days) (median [IQR])	19.00 [14.00, 27.50]
Postoperative complications (%)	
Yes	109 (64.9)
No	50 (29.8)
NA	9 (5.4)
Hemorrhage (%) ^{*†}	
Yes	22 (13.1)
No	87 (51.8)
NA	59 (35.1)
Fistula (%) ^{*†}	
Yes	42 (25.0)
Fistula grade (%)	
1 A	22 (52.4)
2 B	13 (31)
3 C	6 (14.3)
NA	1 (2.4)
No	66 (39.3)
NA	60 (35.7)
Dindo-Clavien classification (%)	
Benign	124 (73.8)
0	63 (37.5)
1	18 (10.7)
2	43 (25.6)
Severe ^{*†}	41 (24.4)

Footnotes : n :total population ; IQR :interquartile range ; kg/m² :kilograms per square meter ; BMI :body mass index ; NA :not available ; MRI :magnetic resonance imaging ; * variable associated with overall survival using univariate Cox proportional-hazards model ; † variable associated with disease free survival using univariate Cox proportional-hazards model

Characteristics	n = 168
3a	11 (6.5)
3b	13 (7.7)
4a	5 (3.0)
4b	2 (1.2)
5	10 (6.0)
NA	3 (1.8)
Follow-up (days) (median [IQR])	651.5 [374, 1077.2]
Adjuvant chemotherapy (%)	141 (83.9)
Number of chemotherapy cycles (median [IQR])	6.00 [5.50, 6.00]
Adjuvant radiotherapy (%)	13 (7.7)
Disease recurrence (%)	128 (76.2)
Local disease recurrence (%)	6 (3.6)
Lymph node recurrence (%)	37 (40.7)
Liver recurrence (%)*	45 (49.5)
Peritoneal recurrence (%)	15 (16.5)
Other (%)	25 (27.5)
Disease-free survival (days) (median [IQR])	363.00 [214.75, 534.25]
Death (%)	114 (67.9)
Footnotes : n :total population ; IQR :interquartile range ; kg/m ² :kilograms per square meter ; BMI :body mass index ; NA :not available ; MRI :magnetic resonance imaging ; * variable associated with overall survival using univariate Cox proportional-hazards model ; † variable associated with disease free survival using univariate Cox proportional-hazards model	

Treatment characteristics

Pancreaticoduodenectomy was performed in 131 patients (78%). Mesenteric superior vein was resected in 69 patients (41.1%). Other organ were resected in only 10 patients (6%) (Table 1B). Median length of hospital stay was 19 days (IQR:14-27.5). TNM stage on the final pathology report was mainly T3 (76.2%) and N1 (76.8%). A median of two lymph nodes were positive at pathological analysis (IQR :1–4) for a lymph node ratio calculated at 0.08 (IQR :0.00-0.2). Postoperative complication data were available in 159 patients (94.6%). Eighty-seven (51.8%) and 66 patients (39.3%) experienced hemorrhage and fistulas, respectively. Post-operative complications were considered severe in 41 patients (24.4%). Ten patients (6%) died of post-operative complications (Dindo-Clavien class 5).

Adjuvant chemotherapy was administered in 141 patients (83.9%), mainly gemcitabine. A median of 6(IQR :5.5-6) chemotherapy cycles were administered. Adjuvant radiotherapy was used for 13 patients (7.7%).

Median follow-up lasted 651.5 days (IQR :374, 1077.2), approximately 21.5 months. Recurrence was identified for 128 patients (76.2%), and classified as distant/metastatic (95.3%, 122 patients), or locoregional (4.7%, 6 patients). A total of 114 (67.9%) patients had died at study endpoint date.

Delay analysis

Median TTD was 9.5 days (IQR :1-30.5). Median TTS was 19 days (IQR :12–36).

Patient characteristics stratified upon TTS inferior to 14 days are presented in Table 2. A total of 59 patients (35%) had their tumor resected less than 14 days after first consultation. Patients in the longer delay group had more frequent vein resections, endoscopic biliary drainage ($p < 0.001$), jaundice ($p = 0.044$), and higher median total serum bilirubin levels ($p < 0.001$).

Table 2
A. Baseline characteristics

Characteristics (n = 168)	≤ 14 days	> 14 days	<i>p</i>
n	59	106	
Male (%)	38 (64.4)	58 (54.7)	0.334
Age (median [IQR])	65.00 [57.00, 69.50]	67 [59, 73]	0.109
BMI (median [IQR])	25.52 [23.20, 29.49]	25.10 [22.50, 28.33]	0.474
Performance status (%)			0.747
0	23 (65.7)	47 (71.2)	
1	10 (28.6)	17 (25.8)	
2	2 (5.7)	2 (3.0)	
Jaundice (%)	47 (79.7)	67 (63.2)	0.044*
Diagnosed during hospital stay (%)	30 (50.8)	45 (42.5)	0.382
Tumor location (%)			0.3
Head	51 (87.9)	82 (78.1)	
Body	3 (5.2)	10 (9.5)	
Tail	4 (6.9)	13 (12.4)	
Lymphadenopathy at imaging (%)	9 (21.4)	18 (20.2)	1
Endoscopic biliary drainage (%)	10 (20.8)	46 (65.7)	< 0.001*
Radiological biliary drainage (%)	1 (2.1)	5 (7.1)	0.422
Total bilirubin (μmol/L) (median [IQR])	173.00 [74.25, 304.50]	21.00 [8.00, 84.75]	< 0.001*
Conjugated bilirubin (μmol/L) (median [IQR])	140.50 [60.50, 236.25]	22.00 [4.00, 76.50]	< 0.001*
Neutrophil-to-lymphocyte ratio (median [IQR])	2.67 [2.06, 4.09]	2.68 [1.92, 3.52]	0.223

Univariate survival analysis using Cox model showed no significant statistical differences with a 14-day TTS threshold (Fig. 2) for DFS ($p = 0.82$) or OS ($p = 0.97$). No difference was shown for DFS either with a 7- ($p = 0.22$), 28- ($p = 0.33$), 60- ($p = 0.79$) or 75- ($p = 0.88$) day delay. OS and DFS were similar in both groups when comparing extreme delays (Table 3). TTD did not impact either DFS or OS, regardless of the delay cut-off (Table 3).

Table 3
Overall and disease-free survival analyses according to different times to decision and time-to-surgery cut-offs.

		Number of patients		Overall Survival			Disease-Free Survival			
	Cut-off	Lower cut-off	Higher cut-off	p	OR	CI 95%	p	OR	CI 95%	
Univariate analysis	Time to decision	≤ 7 days vs. > 7 days	18	147	0.59	0.89	0.57–1.38	0.56	0.88	0.58–1.34
		≤ 14 days vs. > 14 days	59	106	0.50	0.86	0.55–1.34	0.56	0.88	0.58–1.34
		≤ 28 days vs. > 28 days	104	61	0.79	1.07	0.65–1.76	0.68	1.10	0.69–1.8
		≤ 60 days vs. > 60 days	151	14	0.78	0.88	0.35–2.19	0.79	1.09	0.6–1.97
		≤ 7 days vs. > 28 days	18	61	0.96	0.98	0.58–1.68	0.97	1.01	0.61–1.68
	Time to surgery	≤ 7 days vs. > 7 days	18	147	0.21	1.43	0.82–2.52	0.22	1.4	0.81–2.41
		≤ 14 days vs. > 14 days	59	106	0.97	0.99	0.67–1.46	0.82	0.95	0.66–1.39
		≤ 28 days vs. > 28 days	104	61	0.38	1.2	0.80–1.77	0.33	1.21	0.83–1.76
		≤ 60 days vs. > 60 days	151	14	0.88	0.95	0.52–1.74	0.79	1.09	0.6–1.97
		≤ 75 days vs. > 75 days	157	8	0.84	0.93	0.3–1.99	0.88	1.06	0.49–2.28
	≤ 7 days vs. > 60 days	18	14	0.34	1.5	0.66–3.41	0.26	1.6	0.71–3.59	
Multivariate analysis*	Time to surgery	≤ 14 days vs. > 14 days	59	104	0.44	1.18	0.76–1.82	0.99	1.00	0.66–1.51

Footnotes : vs :versus ; OR :odds ratio ; CI 95% :confidence interval 95% ; * Adjusted analysis for vein resection, jaundice, and hemorrhage

Adjusted OS (on organ and vein invasion, severe complications, and adjuvant chemotherapy) and adjusted DFS (on vein invasion, organ resection, severe complications, R status, N status, and adjuvant chemotherapy) were not significantly improved with a shorter TTS, inferior or equal to 14 days ($p = 0.44$ (Table 3)).

Delay had no influence on the occurrence of Fistula ($p = 0.44$), hemorrhage ($p = 0.35$) and severe post-operative complication ($p = 1$)(Table 4). Multivariate logistic regression analysis adjusted on significant factors selected from the univariate analyses did not show any statistical significance concerning fistula ($p = 0.41$), severe post-operative complication ($p = 0.82$) or hemorrhage ($p = 0.59$)(Table 4).

Table 4
Univariate and multivariate analysis comparing the 90-day postoperative morbidity for a 14-days time to surgery.

	≤ 14 days (N = 59)	> 14 days (N = 106)	Univariate analysis	Multivariate analysis	
	n (%)	n (%)	p	p	OR [CI95%]
Hemorrhage (versus absence)*	10 (25.6)	11 (16.2)	0.351	0.59	1.34 [0.46–3.94]
Fistula (versus absence) [†]	12 (31.6)	28 (41.2)	0.442	0.41	0.66 [0.24–1.16]
Severe complications (versus Clavien < 3) [°]	15 (25.4)	26 (24.5)	1	0.82	0.75 [0.06-9]
Footnotes : <i>n</i> :number of patient ; <i>N</i> :total per category					
* :adjusted for jaundice, superior mesenteric vein invasion, and T status					
[†] :adjusted for jaundice, tumor localization and type of resection					
[°] :adjusted for body mass index, lymph node invasion, invaded/sampled lymph nodes ratio and superior mesenteric vein invasion					

Discussion

In our study, TTS had no impact on DFS and OS in patients with upfront resected PA. Similar rates of hemorrhage, fistula, or severe post-operative complications were observed regardless of TTS. This is the first study to evaluate the impact of TTS on the 90-day morbidity.

Shortening time to treatment has been a promising approach to improve survival. TTS has been set as a quality care index in other malignancies(6, 7, 21, 22). As an example, HCC radiofrequency ablations warrant an under five-week management delay to avoid any impact on prognosis(6).

In PA, TTS impact remains unclear. Our results are consistent with most of the previous cohorts that showed no significant influence of TTS on survival rate for patients undergoing a curative intent resection for PA(15, 17, 23). Eshuis et al. concluded that biliary drainage and prolonged TTS do not impair survival rates in a randomized controlled trial(24). On the contrary, Swords et al. showed a modestly improved OS (1.8 months) and a higher 30 and 90-day post-operative mortality in shorter TTS, but at the cost of including a large number of patients(25). Subgroup analysis suggested that shorter TTS could improve resectability rate and prognosis in small tumors(15, 25, 26). Finally, none of these studies analyzed the consequences of shorter TTS on postoperative complications such as hemorrhage, fistulas or Dindo-Clavien classification.

Published studies, including ours, have failed to demonstrate a significant survival benefit with shorter delays before upfront surgery in PA. However, PA arises from pancreatic parenchyma decades before being symptomatic and diagnosed, suggesting slow growth at early stages(27). There is also evidence to support the rapid growth of PA, in later natural history once diagnosed, with an estimated time to progression from a T1 to a T4 stage of approximately 14 months(28). Tumor volume growth could thereby be considered as a factor distinct from the disease stage. Marchegiani et al. showed a TTS effect on survival for smaller tumors (T1 and T2)(26). Shorter TTS could impact resectability and disease-free survival in this specific patient subgroup. In our study, only 28 patients (16.7%) had a T1 or T2 disease stage, making subgroup analyses futile.

Nevertheless, median TTS seems to be increasing year after year due to the incremental PA incidence and the frequent referral to expert centers(21). As TTS has no or little impact on prognosis, management strategy could be modified to allow sufficient time to confirm diagnosis in ambivalent cases and integrate preoperative chemotherapy and prehabilitation strategy. A 28-day minimum delay between last liver imaging and surgery remains well established to avoid any curative surgery performed on patients with liver metastases(3).

No link was observed for fistula, hemorrhage, or severe post-operative complications when TTS was shortened. Post pancreatectomy hemorrhage is mainly due to anastomotic leaks causing pseudoaneurysms(29). Also, when performed early, these interventions are less likely to be the subject of technical debate in multidisciplinary surgical meetings and patients may be less well prepared (uncorrected coagulation, nutritional status, or jaundice). Moreover, significantly higher median bilirubin in the shorter delay group can lead to troubled hemostasis, facilitating post-operative hemorrhage(30).

Our study has several limitations. First, patients with macroscopically incomplete resection (R2) or those who finally did not undergo a curative surgery, despite an initially resectable primary tumor, were not included. These patients could potentially have longer delays explaining tumor progression. Unfortunately, they were not considered in our analysis avoiding performing an intention-to-treat analysis. Furthermore, patients who waited longer without any treatment but finally underwent a curative surgical procedure may have had slower-progressive disease with a better prognosis. Preselecting candidates for curative surgery on their time to progression in the setting of such an aggressive disease seems unethical. Also, 116 patients (69%) were diagnosed upon jaundice presentation, while only 64 (38.1%) experienced a radiological or endoscopic biliary drainage. Patients treated before 2010 were more frequently resected with higher bilirubin levels. Moreover, the power of the study could be insufficient due to the limited number of inclusion centers and retrospectively included patients. Finally, three of the four inclusion centers, including 92.9% of the patients, were tertiary hospitals. We cannot exclude a selection bias and a confusion effect due to highly skilled techniques developed in these centers with low complication rates.

Surgery remains the only existing treatment to cure PA(3). Recent progress with polychemotherapy regimens and better patient selection for surgery has modestly improved overall survival(31, 32). Moreover, new management strategies including neoadjuvant and induction chemotherapies are to be interpreted differently from passive delay where no therapeutic interventions occur. New perspectives must be found to increase the survival and quality of life of these patients. PA may not be the most suitable malignancy to study TTS as a quality metric(33). However, the COVID-19 pandemic has called for urgent case hierarchization and has thereby raised new questions about carcinologic surgical priorities. Ongoing multicentric CAPANCOVID-19 (<https://clinicaltrials.gov/ct2/show/NCT04406571>) tries to measure the impact of the COVID-19 pandemic causing prolonged management delay, from surgery to palliative situations.

We showed that TTS seems to have no impact on OS, DFS and 90-day postoperative morbidity. Other trials need to be carried out to understand the role of TTS in smaller tumor sizes.

Declarations

Acknowledgments : Université de Reims Champagne Ardennes supported this study. The authors thank the technical assistance of Grace Stockton-Bliard for English editing.

Ethics approval and consent to participate : The institutional review board at Reims University Hospital approved this study. Patients' verbal consents were collected in accordance with the protocol MR004 from the Commission Nationale de l'Informatique et des Libertés (n°2206749, 13/09/2018), and followed the French authorities' requirements.

Consent to publish : Not Applicable

Availability of data and materials : The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests : *M Brugel, R Kianmanesh, L Teuma, A Tashkandi, B Royer, R Rhaïem, C Perrenot, T Piardi, S Deguelte* : none ; *O Bouché* : speaker honoraria/advisory role for Merck KGaA, Roche Genentech, Bayer, Astra-Zeneca, Grunenthal, MSD, Amgen, Pierre Fabre, Servier outside the submitted work, *JM Regimbeau* : advisory role for Quantum Robotics outside the submitted work ; *P Pessaux* : orator for Integra and 3M, co-founder of Virtualisurg outside the submitted work ; *C Neuzillet* : consultancy/honoraria: Pierre Fabre, Servier, Roche, AstraZeneca, Bristol-Myers Squibb, Amgen, Merck, MSD, Novartis, Incyte Biosciences, Mylan, Baxter, Nutricia, Fresenius Kabi ; research funding: Roche ; clinical trials: OSE Immunotherapeutics, AstraZeneca, Bristol-Myers Squibb outside the submitted work

Funding : No funding was obtained for this study.

Author's contributions : MB performed all statistical analyzes including tables and figures, wrote, reviewed and edited the

original and final draft. OB, RK and SD conceptualized this study, supervised, validated, wrote, reviewed, and edited the final draft. LT conceptualized the study, collected data, reviewed, and edited the final draft. AT wrote, reviewed and edited the original and final draft. JR, PP, BR, RR, CP CN and TP supervised, reviewed and validated the final draft. All authors read and approved the final manuscript.

References

1. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. *World J Oncol.* févr 2019;10(1):10–27.
2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. *Cancer Res.* 1 juin 2014;74(11):2913–21.
3. Neuzillet C, Gaujoux S, Williet N, Bachet J-B, Baugeon L, Colson Durand L, et al. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). *Dig Liver Dis.* déc 2018;50(12):1257–71.
4. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. *N Engl J Med.* 2011;9.
5. Santos F, Dragomir A, Kassouf W, Franco E, Aprikian A. Urologist referral delay and its impact on survival after radical cystectomy for bladder cancer. *Curr Oncol Tor Ont.* févr 2015;22(1):e20-26.
6. Chen W-T, Fernandes ML, Lin C-C, Lin S-M. Delay in treatment of early-stage hepatocellular carcinoma using radiofrequency ablation may impact survival of cirrhotic patients in a surveillance program. *J Surg Oncol.* févr 2011;103(2):133–9.
7. Eaglehouse YL, Georg MW, Shriver CD, Zhu K. Time-to-surgery and overall survival after breast cancer diagnosis in a universal health system. *Breast Cancer Res Treat.* nov 2019;178(2):441–50.
8. Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. *BMJ.* 4 nov 2020;371:m4087.
9. Lukács G, Kovács Á, Csanádi M, Moizs M, Repa I, Kaló Z, et al. Benefits Of Timely Care In Pancreatic Cancer: A Systematic Review To Navigate Through The Contradictory Evidence. *Cancer Manag Res.* 2019;11:9849–61.
10. Swanson RS, Pezzi CM, Mallin K, Loomis AM, Winchester DP. The 90-Day Mortality After Pancreatectomy for Cancer Is Double the 30-Day Mortality: More than 20,000 Resections From the National Cancer Data Base. *Ann Surg Oncol.* déc 2014;21(13):4059–67.
11. Neuzillet C, Anota A, Foucaut A, Védie A, Antoun S, Barnoud D, et al. Nutrition and Physical Activity: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC, SFP-APA, SFNCM, AFSOS). *BMJ Support Palliat Care.* 2020; in press
12. Bates A, West MA, Jack S. Framework for prehabilitation services: Framework for prehabilitation services. *Br J Surg.* janv 2020;107(2):e11–4.
13. Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, et al. Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). *Surgery.* juin 2014;155(6):977–88.
14. Dindo D, Demartines N, Clavien P-A. Classification of Surgical Complications. *Ann Surg.* août 2004;240(2):205–13.
15. Sanjeevi S, Ivanics T, Lundell L, Kartalis N, Andrén-Sandberg Å, Blomberg J, et al. Impact of delay between imaging and treatment in patients with potentially curable pancreatic cancer. *Br J Surg.* févr 2016;103(3):267–75.
16. Yun YH, Kim YA, Min YH, Park S, Won YJ, Kim DY, et al. The influence of hospital volume and surgical treatment delay on long-term survival after cancer surgery. *Ann Oncol Off J Eur Soc Med Oncol.* oct 2012;23(10):2731–7.
17. Raptis DA, Fessas C, Belasyse-Smith P, Kurzawinski TR. Clinical presentation and waiting time targets do not affect prognosis in patients with pancreatic cancer. *Surg J R Coll Surg Edinb Irel.* oct 2010;8(5):239–46.
18. GERCOR - Multidisciplinary Oncology Cooperative Group. Management of Symptomatic Advanced Pancreatic Adenocarcinoma: « Urgence Pancreas » - A Prospective A.R.C.A.D Cohort Study [Internet]. clinicaltrials.gov; 2019 févr [cité 7

- oct 2020]. Report No.: NCT02979483. Disponible sur: <https://clinicaltrials.gov/ct2/show/NCT02979483>
19. Neal RD, Tharmanathan P, France B, Din NU, Cotton S, Fallon-Ferguson J, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. *Br J Cancer*. 31 mars 2015;112 Suppl 1:S92-107.
 20. Kaltenmeier C, Shen C, Medich DS, Geller DA, Bartlett DL, Tsung A, et al. Time to Surgery and Colon Cancer Survival in the United States. *Ann Surg* [Internet]. 18 sept 2020 [cité 21 sept 2020]; Publish Ahead of Print. Disponible sur: https://journals.lww.com/annalsofsurgery/Abstract/9000/Time_to_Surgery_and_Colon_Cancer_Survival_in_the.94742.aspx
 21. Paterson WG, Depew WT, Paré P, Petrunia D, Switzer C, van Zanten SJV, et al. Canadian consensus on medically acceptable wait times for digestive health care. *Can J Gastroenterol*. juin 2006;20(6):411–23.
 22. Jooste V, De Jardin O, Bouvier V, Arveux P, Maynadie M, Launoy G, et al. Pancreatic cancer: Wait times from presentation to treatment and survival in a population-based study. *Int J Cancer*. 01 2016;139(5):1073–80.
 23. Swords DS, Zhang C, Presson AP, Firpo MA, Mulvihill SJ, Scaife CL. Association of time-to-surgery with outcomes in clinical stage I-II pancreatic adenocarcinoma treated with upfront surgery. *Surgery*. 2018;163(4):753–60.
 24. Marchegiani G, Andrianello S, Perri G, Secchettin E, Maggino L, Malleo G, et al. Does the surgical waiting list affect pathological and survival outcome in resectable pancreatic ductal adenocarcinoma? *HPB*. 2018;20(5):411–7.
 25. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. *Nature*. oct 2010;467(7319):1114–7.
 26. Yu J, Blackford AL, dal Molin M, Wolfgang CL, Goggins M. Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. *Gut*. nov 2015;64(11):1783–9.
 27. Wente MN, Veit JA, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, et al. Postpancreatectomy hemorrhage (PPH)—An International Study Group of Pancreatic Surgery (ISGPS) definition. *Surgery*. juill 2007;142(1):20–5.
 28. Papadopoulos V, Filippou D, Manolis E, Mimidis K. Haemostasis impairment in patients with obstructive jaundice. *J Gastrointest Liver Dis JGLD*. juin 2007;16(2):177–86.
 29. Mattevi C, Garnier J, Marchese U, Ewald J, Gilibert M, Poizat F, et al. Has the non-resection rate decreased during the last two decades among patients undergoing surgical exploration for pancreatic adenocarcinoma? *BMC Surg*. 5 août 2020;20(1):176.
 30. Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul J-L, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. *N Engl J Med*. 20 déc 2018;379(25):2395–406.
 31. Mirkin KA, Hollenbeak CS, Wong J. Time to Surgery: a Misguided Quality Metric in Early Stage Pancreatic Cancer. *J Gastrointest Surg Off J Soc Surg Aliment Tract*. 2018;22(8):1365–75.
 32. Eshuis WJ, van der Gaag NA, Rauws EAJ, van Eijck CHJ, Bruno MJ, Kuipers EJ, et al. Therapeutic delay and survival after surgery for cancer of the pancreatic head with or without preoperative biliary drainage. *Ann Surg*. nov 2010;252(5):840–9.

Figures




Figure 1

Flowchart n :total population ; R :resection status







Figure 2

Disease-free and overall survival according to time to surgery and time to decision. A. Disease-free survival according to time to surgery ($p = 0.82$); B. Overall survival according to time to surgery ($p = 0.97$); C. Disease free survival according to time to decision ($p = 0.56$); D. Overall survival according to time to decision ($p = 0.5$);